Banque Cantonale Vaudoise’s BridgeBio Pharma BBIO Stock Holding History

Banque Cantonale Vaudoise’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$186K	Buy	+2,500	New	+$175K	0.03%	162

Other funds holding BBIO

Jupiter Topco New York $245B AUM

KKRC

Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

ACM

Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Banque Cantonale Vaudoise's BBIO Position: Q2 2026 in Review

Banque Cantonale Vaudoise opened a new position in BridgeBio Pharma (BBIO) in Q2 2026: 2,500 shares worth $186K. The stake represents 0.03% of the portfolio and ranks #162 among its holdings.

474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

Banque Cantonale Vaudoise held 2,500 shares of BridgeBio Pharma worth $186K as of Q2 2026.
BridgeBio Pharma was a new Banque Cantonale Vaudoise position in Q2 2026.
BridgeBio Pharma made up 0.03% of Banque Cantonale Vaudoise's portfolio in Q2 2026, its #162 holding.
474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Banque Cantonale Vaudoise's 13F filing for Q2 2026, filed 31 Jul 2026.